Skip to content
Cefotaxime
Claforan (cefotaxime) is a small molecule pharmaceutical. Cefotaxime was first approved as Claforan on 1982-01-01. It is used to treat acinetobacter infections, bacterial infections, bacterial meningitis, bacterial pneumonia, and bacterial skin diseases amongst others in the USA.
Download report
Favorite
Searched
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
musculoskeletal diseasesD009140
digestive system diseasesD004066
respiratory tract diseasesD012140
nervous system diseasesD009422
urogenital diseasesD000091642
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cefotaxime sodium
Tradename
Company
Number
Date
Products
CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINERB. Braun MedicalN-050792 DISCN2004-07-29
1 products
CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINERB. Braun MedicalN-050792 DISCN2004-07-29
1 products
CLAFORANValidus PharmaceuticalsN-050547 DISCN1982-01-01
4 products, RLD
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERValidus PharmaceuticalsN-050596 DISCN1985-05-20
1 products
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINERValidus PharmaceuticalsN-050596 DISCN1985-05-20
1 products
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERValidus PharmaceuticalsN-050596 DISCN1985-05-20
1 products
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINERValidus PharmaceuticalsN-050596 DISCN1985-05-20
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
cefotaximeunapproved drug for use in drug shortage2020-11-13
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
acinetobacter infectionsEFO_1000792D000151—
bacterial infections—D001424A49
bacterial meningitisEFO_1000831D016920G00
bacterial pneumoniaEFO_1001272D018410J15.9
bacterial skin diseases—D017192—
bacteroides infectionsEFO_1000832D001442—
clostridium infectionsEFO_1000874D003015A05.2
escherichia coli infectionsEFO_1001318D004927B96.20
fusobacterium infectionsEFO_1000943D005674—
gonorrheaDOID_7551D006069A54
Show 14 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01D: Other beta-lactam antibacterials in atc
— J01DD: Third-generation cephalosporins
— J01DD01: Cefotaxime
— J01DD51: Cefotaxime and beta-lactamase inhibitor
HCPCS
Code
Description
J0698
Injection, cefotaxime sodium, per gm
Clinical
Clinical Trials
36 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver cirrhosisD008103EFO_0001422K74.0———2—2
Ventilator-associated pneumoniaD053717EFO_1001865J95.851———112
Urinary tract infectionsD014552EFO_0003103N39.0———2—2
Critical illnessD016638———112
Communicable diseasesD003141———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SepsisD018805A41.9——1—23
Lung diseasesD008171EFO_0003818J98.4—11——1
Pancreatic neoplasmsD010190EFO_0003860C25——1——1
Pancreatic diseasesD010182K86.9——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AppendicitisD001064EFO_0007149K37—1——12
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bacterial infectionsD001424A491———12
Brain injuriesD001930S06.91————1
Focus groupsD0171441————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Infectious pregnancy complicationsD011251————11
Neonatal sepsisD000071074HP_0040187————11
Respiratory distress syndromeD012128EFO_1000637J80————11
Respiratory tract infectionsD012141J06.9————11
PneumoniaD011014EFO_0003106J18————11
Antibiotic prophylaxisD019072————11
InfectionsD007239EFO_0000544————11
Bile duct neoplasmsD001650————11
Klatskin tumorD018285EFO_1001005————11
CholedocholithiasisD042883EFO_1000865————11
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCEFOTAXIME
INNcefotaxime
Description
Cefotaxime is a cephalosporin compound having acetoxymethyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups. It has a role as a drug allergen and an antibacterial drug. It is a member of 1,3-thiazoles, an oxime O-ether and a cephalosporin. It is a conjugate acid of a cefotaxime(1-).
Classification
Small molecule
Drug classcephalosporins
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(C)=O)CS[C@H]12)c1csc(N)n1
Identifiers
PDB—
CAS-ID63527-52-6
RxCUI2186
ChEMBL IDCHEMBL1730
ChEBI ID204928
PubChem CID5742673
DrugBankDB00493
UNII IDN2GI8B1GK7 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 28,140 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
37 adverse events reported
View more details